Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Andreas W. Machl
Observed names:
A. Machl,
A. W. Machl,
A.W. Machl,
AW Machl,
Andreas Machl,
Andreas W Machl
show all 6
Institutions:
EMD Serono, Inc. (United States),
Merck Healthcare KGaA, Darmstadt (Germany)
Observed institutions:
Roche Pharma AG (Germany),
EMD Serono, Inc. (United States),
Merck Healthcare KGaA, Darmstadt (Germany)
OpenAlex ID:
A5111785352
Bintrafusp Alfa Versus Pembrolizumab in Patients With Treatment-Naive, Programmed Death-Ligand 1–High Advanced NSCLC: A Randomized, Open-Label, Phase 3 Trial
2023
·
Byoung Chul Cho
, Jong Seok Lee
, et al.
·
Journal of Thoracic Oncology
·
98
PDF
SEMP1, a senescence-associated cDNA isolated from human mammary epithelial cells, is a member of an epithelial membrane protein superfamily
1999
·
Karen Swisshelm
, Andreas Machl
, et al.
·
Gene
·
89
Phase 2 trial of bintrafusp alfa as second-line therapy for patients with locally advanced/metastatic biliary tract cancers
2023
·
Changhoon Yoo
, Milind M. Javle
, et al.
·
Hepatology
·
53
Discovery of Small-Molecule Selective mTORC1 Inhibitors via Direct Inhibition of Glucose Transporters
2019
·
Seong A. Kang
, David J. O'Neill
, et al.
·
Cell chemical biology
·
49
PDF
Bintrafusp Alfa: A Bifunctional Fusion Protein Targeting PD-L1 and TGF-β, in Patients with Pretreated Colorectal Cancer: Results from a Phase I Trial
2022
·
Alexander Spira
, Michael S Wertheim
, et al.
·
The Oncologist
·
34
PDF
M2698 is a potent dual-inhibitor of p70S6K and Akt that affects tumor growth in mouse models of cancer and crosses the blood-brain barrier.
2016
·
Andreas Machl
, Erik W Wilker
, et al.
·
PubMed
·
31
Phase I study of peposertib and avelumab with or without palliative radiotherapy in patients with advanced solid tumors
2024
·
B. Perez
, R. Aljumaily
, et al.
·
ESMO Open
·
25
DNA microarray technology and antimicrobial drug discovery
2000
·
Igor Ivanov
, Christoph Schaab
, et al.
·
Pharmacogenomics
·
23
Efficacy, safety, and biomarker analyses of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with advanced non-small cell lung cancer
2024
·
Arun Rajan
, Houssein Abdul Sater
, et al.
·
Journal for ImmunoTherapy of Cancer
·
21
PDF
Improving DNA array data quality by minimising 'neighbourhood' effects
2002
·
A. W. Machl
·
Nucleic Acids Research
·
13
PDF
Identification of Clinical Candidate M2698, a Dual p70S6K and Akt Inhibitor, for Treatment of PAM Pathway-Altered Cancers
2021
·
Lizbeth DeSelm
, Bayard Huck
, et al.
·
Journal of Medicinal Chemistry
·
12
Identification of a novel c-DNA overexpressed in Fanconi's anemia fibroblasts partially homologous to a putative l-3-phosphoserine-phosphatase
1998
·
Simone A Planitzer
, Andreas W Machl
, et al.
·
Gene
·
10
A novel, membrane receptor-based retroviral vector for Fanconi anemia group C gene therapy
1997
·
AW Machl
, S Planitzer
, et al.
·
Gene Therapy
·
10
Tumor growth inhibition modeling in patients with second line biliary tract cancer and first line non‐small cell lung cancer based on bintrafusp alfa trials
2023
·
Ana‐Marija Milenković‐Grišić
, Nadia Terranova
, et al.
·
CPT Pharmacometrics & Systems Pharmacology
·
7
PDF
Discovery of 4-aminopyrimidine analogs as highly potent dual P70S6K/Akt inhibitors
2021
·
Yufang Xiao
, Bayard R. Huck
, et al.
·
Bioorganic & Medicinal Chemistry Letters
·
4
Applicability of nonsyngeneic cell models for screening of genes in monogenetics diseases via differential display technique
1997
·
Simone A. Planitzer
, Andreas W. Machl
, et al.
·
Electrophoresis
·
4
Small deletions in the regulatory 3′ UTR of the human α-tropomyosin gene identified by differential display
1998
·
Simone A Planitzer
, Andreas W Machl
, et al.
·
Molecular and Cellular Probes
·
3
l-NGFR receptor is a new flow cytometric tool for rapid cell cycle-correlated gene therapy complementation studies in viable cells
1997
·
A.W. Machl
, S.A. Planitzer
, et al.
·
Cytometry
·
3
Abstract #3698: Efficacy of MEK inhibitor AS703026 in various primary tumor explants.
2009
·
Andreas Machl
, Janet Ogden
, et al.
·
Cancer Research
·
2
Abstract 4516: Evaluation of p70S6K/Akt inhibitor MSC2363318A in patient derived xenograft (PDX) models of breast cancer
2014
·
Bayard R. Huck
, H Tian
, et al.
·
Cancer Research
·
1
Plasma epigenomic profiling for identification of mechanisms of sensitivity, primary and acquired resistance to tepotinib in METex14 skipping metastatic NSCLC.
2026
·
Sunny Das
, Robert Fisher
, et al.
·
Journal of Clinical Oncology
Comprehensive plasma-based epigenomic profiling from INTR@PID Lung 037 study samples to identify pathways associated with response and resistance to pembrolizumab in PD-L1–high NSCLC.
2026
·
Robert Fisher
, Sunny Das
, et al.
·
Journal of Clinical Oncology
Abstract 3884: Multiplex immunofluorescence based spatial analysis of HER2 positive breast cancer patients treated with bintrafusp alfa: A translational pathology study.
2026
·
Maria Gabriela Raso
, Elizve N. Barrientos-Toro
, et al.
·
Cancer Research
Abstract 6179: Machine learning (ML)-spatial quantification of the tumor microenvironment (TME) identifies differences associated with response to bintrafusp alfa (BA) vs pembrolizumab (PEM) treatment in the Phase 3 INTR@PID Lung 037 study
2024
·
John Abel
, Andreas Machl
, et al.
·
Cancer Research
Retrospective clinical analysis of circulating tumor DNA (ctDNA)–based molecular response (MR) and baseline blood-based tumor mutational burden (bTMB) for monitoring response in phase 3 trial of bintrafusp alfa vs. pembrolizumab treatment of non-small cell lung cancer (NSCLC).
2023
·
Zheng Feng
, Andreas Machl
, et al.
·
Journal of Clinical Oncology
Show more works
View as search
Works count:
28
Citation count:
492
H-index:
11
I10-index:
13
Year
Topic
Type
